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Abstract
Cancer cell metabolism has received increasing attention. Despite
a boost in the application of clinical metabolic profiling (CMP) in
cancer patients, a meta-analysis has not been performed. The
primary goal of this study was to assess whether public accessibil-
ity of metabolomics data and identification and reporting of
metabolites were sufficient to assess which metabolites were
consistently altered in cancer patients. We therefore retrospec-
tively curated data from CMP studies in cancer patients published
during 5 recent years and used an established vote-counting
method to perform a semiquantitative meta-analysis of metabo-
lites in tumor tissue and blood. This analysis confirmed well-
known increases in glycolytic metabolites, but also unveiled
unprecedented changes in other metabolites such as ketone bodies
and amino acids (histidine, tryptophan). However, this study also
highlighted that insufficient public accessibility of metabolomics
data, and inadequate metabolite identification and reporting
hamper the discovery potential of meta-analyses of CMP studies,
calling for improved standardization of metabolomics studies.
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Introduction
Clinical metabolomics investigates how metabolite levels are altered
in various (patho)physiological conditions, often with the objective
to find new roles of metabolism in disease, to discover novel meta-
bolic drug targets, or to identify biomarkers (Fernie et al, 2004).
Hopes have been raised that clinical metabolic profiling (CMP)
could reshape our understanding of cell biology and pathophysiol-
ogy, and even improve clinical practice (Patti et al, 2012). However,
apart from a few high-profile discoveries (Dang et al, 2009; Wang
et al, 2011), these expectations have not been fully met and the
impact of CMP studies has remained relatively modest (Sevin et al,
2015). This has raised concerns about the robustness, consistency,
and translational potential of CMP studies (Gika et al, 2014). In
contrast, the clinical impact of transcriptomics, genomics, and
proteomics has greatly benefited from standardized data reporting
and accessibility, permitting efficient data mining and quantitative
meta-analyses (Fernie et al, 2004; Rosenberg et al, 2010; Hu et al,
2013a,b; Nilsson et al, 2014).
Tools have been developed to deposit CMP results in databases
for managing (meta)data of metabolome analyses, but not for
performing meta-analyses (Haug et al, 2013; Ara et al, 2015; Salek
et al, 2015; Rocca-Serra et al, 2016). Surprisingly, however, even
though descriptive meta-studies that overview CMP data have been
reported (Shah et al, 2012; Abbassi-Ghadi et al, 2013; Huynh et al,
2014; Nickler et al, 2015; Guasch-Ferre et al, 2016), not a single
study performed a quantitative meta-analysis, in particular in
cancer. Nonetheless, the aggregation of information from multiple
studies in a meta-analysis leads in many cases to higher statistical
(discovery) power and therefore higher impact of individual studies
(Green, 2005). It remains undetermined whether a meta-analysis of
cancer CMP studies would offer novel insight, since cancer is a
heterogeneous disease, and CMP studies greatly vary in (i) how and
how many metabolites are measured, identified, and reported; (ii)
how such studies are designed; and (iii) whether and how they are
validated (Dunn et al, 2012). Only very recently, the first in class
meta-analysis of CMP was reported. However, this meta-analysis
was performed only on a subset of prospective CMP studies in
diabetic patients and even though this study associated elevated
plasma levels of branched-chain amino acids with the risk of devel-
oping type 2 diabetes (T2DM), it did not attempt to aggregate and
analyze the data of all the metabolites reported in all individual
studies (Guasch-Ferre et al, 2016).
For genomics, transcriptomics and proteomics data, the availabil-
ity of raw data such as abundances of transcript and protein levels
offers the possibility to compare the datasets in their original form
(Brazma et al, 2003; Jones et al, 2006; Barrett et al, 2013). When
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such quantitative data are not available, the results can still be
analyzed in a semiquantitative meta-analysis by vote counting, a
technique that is generally applicable and does not rely on the avail-
ability of raw data (Rikke et al, 2015). Vote counting has been
successfully used in previous meta-analyses to identify metabolic
targets, the expression of which was consistently deregulated across
multiple cancer types (Nilsson et al, 2014).
In this study, focusing on cancer, we retrospectively generated a
curated list of metabolites, based on MEDLINE search filter criteria,
from previous CMP studies in cancer patients published during 5 recent
years, and used vote counting to perform a semiquantitative meta-
analysis. The primary goal of this study was to assess whether public
accessibility of metabolomics data, metabolite identification and report-
ing were sufficient to obtain, novel insight in consistent metabolite
changes in cancer patients. It was not the primary goal of this study to
identify new metabolic drug targets or biomarkers, or to create a
comprehensive, widely useful cancer metabolite database per se.
Rather, we explored whether a meta-analysis of CMP studies is feasible,
and how these CMP studies can be improved to meet the same stan-
dards as routinely used in the genomics, transcriptomics and proteo-
mics fields.
Results
Compilation of a curated cancer metabolomics dataset
Since deposition of metabolomics data in publicly available repos-
itories is generally not required by scientific journals to date,
comprehensive datasets for meta-analysis have to be created by
alternative approaches, for instance, by retrospective manual
curation. We therefore conducted a systematic review of the liter-
ature to identify all CMP studies in cancer published between
June 2010 and June 2015. For all studies, we extracted data on
key methodological parameters using a pre-defined data extraction
protocol such as the type of disease, number of patients included,
the analytical platform, outcome measures, the level of metabolite
identification, and major findings among others. We also
extracted information on all reported metabolites, such as raw
abundance, fold change, and whether a metabolite was up- or
downregulated in cancer. Because the vast majority of studies
reported metabolites using ambiguous common names but not
unique identifiers, we used (bio)informatics tools to extensively
curate the extracted data of each study (see Materials and Meth-
ods). The resulting collection contains curated quality-checked
data of 136 cohorts reported in 126 studies, spanning 18 tumor
types and over 5,300 “disease versus control” comparisons of
approximately 1,900 unique metabolites in blood, urine, and
tumor tissue (denoted as “tissue” from here onwards) from an
estimated 21,000 individuals (Fig 1 for study outline; Table EV1;
see Materials and Methods for details).
Clinical metabolic profiling: methods and limitations
Data reporting
To assess how complete the reporting of the measured metabolites
was done relative to all previously reported metabolites, we
indicated for each study whether the metabolite was reported or
not. Current metabolic profiling technologies are capable of measur-
ing tens to hundreds of metabolites. However, surprisingly, most
individual studies published only a very small subset of all earlier
reported metabolites. This is clearly visible from the heat maps
shown in Fig 2A (for blood) and Fig EV1A and B (for tumor tissue
and urine), where a dark blue mark denotes that the metabolite was
reported to be increased or reduced in cancer. From the abundant
white “empty” space, it is obvious that reporting of metabolites was
highly incomplete. Even metabolites associated with a major chemi-
cal class (such as amino acids, carbohydrates) were reported on
average in only 6.4% of the studies. This finding can be explained
in part by the use of different profiling methodologies across
studies.
Notably, however, the majority of studies reported only metabo-
lites presumably deemed to be relevant to the authors and used
heterogeneous statistical outcome measures without providing full
datasets (Table 1). In fact, even though CMP studies have the poten-
tial to assess many hundreds of metabolites, the median number of
reported metabolites per study was only 22 (Table 1). Moreover,
while most, but not all, studies provided information regarding the
magnitude of the change (“effect size”), only 22.8% of the studies
reported measures of variance (Table 1). Also, only a mere 18.7%
of all studies reported data on all measured metabolites.
Taken together, it appears that in general, metabolite reporting
was highly incomplete and presumably subjective. This is in sharp
contrast to the genomics, proteomics, and transcriptomics analyses,
where full dataset deposition in publically available repositories is
often required.
Metadata reporting
Cancer is a heterogeneous disease. Therefore, cancer patients are
often clinically stratified based on demographic factors (such as age
and gender), tumor staging, histological parameters, molecular
tumor characteristics, treatment response, and others. However, it
is generally acknowledged that clinical and experimental metadata
reporting is problematic in most CMP studies, thus not only for
cancer (Ara et al, 2015). Indeed, we noticed that metadata have
been only scarcely reported, even though specialized databases exist
to collect such data from metabolic profiling experiments specifi-
cally (Ara et al, 2015). This precluded us from factoring patient and
tumor heterogeneity into our meta-analysis.
Study design
A total of 122 of the CMP studies (96.8%) included in our study
employed an observational, cross-sectional research design, in
which cancer patients were compared to a control group at a
particular time point. While such CMP studies may discriminate
between cancer and control and could provide novel insight in
disease pathogenesis, such experimental design is not (necessar-
ily) optimal to discover novel metabolic biomarkers for patient
stratification. A major goal of modern medicine is to stratify
patients for personalized treatment and to identify biomarkers
that can predict disease course or treatment response. However,
the majority of CMP studies did not consider any factors that
could aid in patient stratification other than the presence of
disease. Also, biomarker discovery and validation requires a
prospective research design in which patients are followed up
over time to associate metabolite levels with the course of disease
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or treatment response. Of the cancer studies we considered, only
4 (3.2%) had a longitudinal research design or compared early
with late-stage cancer to assess metabolic alterations over the
course of disease.
Metabolite identification
Metabolite identification is a major bottleneck in CMP, but is
nonetheless essential for adequate biological interpretation of the
results. The Metabolomics Standards Initiative (see http://cosmos
-fp7.eu/msi for more information) defined four levels of identifi-
cation, of which only “level one” results in unambiguous annotation
(Salek et al, 2013). Notably, only half (52%) of the CMP studies
provided “level one” metabolite identification for at least a subset of
the reported metabolites, and even fewer studies identified all
reported metabolites unambiguously, often studies that profiled a
small set or specific class of metabolites.
Clinical or orthogonal validation
Metabolic profiling produces high-dimensional data (a typical
dataset may contain values for hundreds to thousands of metabolites
for each sample analyzed). Statistical analysis of such data is prone
to type I errors (“false positives”). Therefore, results should be best
validated in independent cohorts or verified by using orthogonal
models or by using different independent technologies (e.g. tran-
scriptomics, proteomics) and/or targeted analysis. However, only
17.9% of the CMP studies reported validation cohorts and only
~10% used orthogonal models. Even though metabolic profiling is
ideally suited to combine with other (orthogonal) omics data, only
6.8% of the studies performed multi-omics analysis (Table EV2).
Thus, the findings of the majority of CMP studies remain uncon-
firmed. In principle, a meta-analysis is useful to validate the results
of individual studies in independent cohorts.
Identification of metabolic signatures in cancer
Incomplete and heterogeneous reporting of metabolite data and
summary statistics prevented us from performing a quantitative
meta-analysis and precluded us from determining the average
fold changes of metabolite levels across all studies for any
metabolite. Also, scarce availability of metadata prevented us
from stratifying cancer patients and from assessing an associa-
tion between metabolite changes and patient or tumor character-
istics. These omissions in data reporting likely explain why
previous metabolomics meta-studies did not perform statistical
aggregation of the results from individual studies (Rocca-Serra
et al, 2016). However, all studies in our dataset reported the
directionality (increased or decreased levels) of the deregulated
metabolites. We therefore performed a meta-analysis by vote
counting (Rikke et al, 2015), a semiquantitative technique that
only requires such information, allowing us to include all studies
in the analysis for improved statistical power. Nonetheless, our
meta-analysis was still (relatively) underpowered, and we
obtained only statistical significance for a subset of metabolites,
even though other metabolites showed clear trends that could
become statistically significant with more power, and hence may
be of clinical relevance.
Meta-analysis approach
To explore how consistently metabolites are altered across cancer
types, we indicated for each metabolite per study whether it was
increased (denoted by “+1”) or decreased (“1”) in cancer patients
relative to controls. These controls were “healthy” individuals with-
out cancer for analysis of blood and urine, and, for tumor tissue,
controls included subjects (i) without cancer, (ii) with premalignant
lesions, or (iii) with cancer but using adjacent healthy tissue as
control. The vote-counting statistic (VCS, reported as VCS/number
of reporting studies; Benjamini–Hochberg adjusted P-value)
assumes a high positive value if the metabolite was consistently
increased and conversely a negative value for consistently decreased
metabolites. In this context, a zero value implies that the studies
provide conflicting evidence on whether the metabolite was
decreased or increased. The Benjamini-Hochberg adjusted P-value
was only calculated for metabolites reported in at least six cohorts.
While the statistical power of urine meta-analysis was limited due
Figure 1. Overview of the study design and dataset compilation.
We included 126 studies in our curated cancer metabolomics dataset, studies that described profiling in multiple cancer types were counted once for each type, giving rise to
136 “cancer versus control” cohorts spanning 18 different cancer types, 71 assessing blood, 39 tissue, and 26 urine. We also included 18 diabetes mellitus type 2 studies to
determine whether our vote-counting method could identify distinct metabolic signatures in cancer versus diabetes.
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to a small number of studies (Fig EV2; Tables EV1 and EV3), our
analysis revealed profiles of consistently deregulated metabolites in
blood (Fig 2B and C; Table EV4) and tumor tissue (Figs 2D and 3;
Table EV5) across cancer types.
Cancer-associated metabolic changes
We then assessed whether the vote-counting method identified
particular metabolites that were consistently up- or downregulated
in cancer. In agreement with the known increase of glycolysis in
cancer cells (Vander Heiden et al, 2009), this analysis showed
increased tumor lactic acid levels consistently across all cancer types
examined (VCS = 26/26, P-value = 1.5 × 106) (Figs 2D and 3).
Interestingly, glutamic acid ranked second (only after lactic acid)
among the most increased metabolites in tumor tissue (VCS = 16/18,
P-value = 3.6 × 103; Figs 2D and 3) and was the most frequently
increased metabolite in blood (VCS = 11/15, P-value = 5.5 × 102;
Fig 2B and C). The glutamic acid precursor glutamine was the
second most decreased metabolite in blood (VCS = 18/26,
P-value = 8.0 × 103) and was frequently increased in tumor tissue
(VCS = 7/13, P-value = 1.1 × 101; Figs 2B–D and 3). The findings
in the blood may indicate systemic depletion of glutamine and
other amino acids (see below) as observed in chronic catabolic
states (Souba, 1993). Overall, this analysis confirms that the vote-
counting method can identify changes in metabolites, which have
been previously implicated in cancer cell metabolism (Lunt &
Vander Heiden, 2011).
A novel finding was that the ketone body 3-hydroxybutyric acid
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Figure 2. Metabolite reporting & vote-counting analysis in tissue and blood.
A Heat map of all reported cancer blood metabolites (each dark blue mark denotes that the metabolite was reported to be increased or decreased) in various cancer
types, illustrating that most individual studies report only a small subset of all previously measured metabolites. It is typically not described whether the metabolites
that were not reported (white “empty” space) were not measured, or measured but not reported. Labeling: x-axis (top): ribbon color code, denoting the cancer type
(right; indicated by red arrow); x-axis (bottom): cohorts, arranged from 1 to 71; y-axis (right): all 1,206 metabolites reported in at least one of the studies; y-axis (left):
ribbon color code, denoting the metabolite class (amino acids, carbohydrates, etc.; “other” refers to all other metabolites than the listed classes). See also Table EV4.
B Vote counting of cancer blood metabolites (reported in at least six cohorts) showed consistently deregulated metabolites. Blue bars: decreased metabolites; red
bars: increased metabolites. An asterisk (*) in front of the name of the metabolite indicates at least a statistical trend (P < 0.1) obtained using the sign test; red
arrowheads denote metabolites mentioned in the main text.
C, D Volcano plots of blood metabolites (C) and tissue metabolites (D), reported in at least six cancer studies, with the vote-counting score on the x-axis and the log10
adjusted P-value on the y-axis. Cyan indicates deregulated metabolites that show a trend (P < 0.1; for blood, corresponding to metabolites marked with * in panel
B; for tissue, corresponding to metabolites marked with * in Fig 3) or statistical significance (P < 0.05; above black dashed horizontal line); red indicates
metabolites with a P-value > 0.1. A subset of metabolites is annotated (see Tables EV4 (blood) and EV5 (tissue) for full annotation, vote-counting statistics were
calculated using the sign test).
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P-value = 1.3 × 101) (Fig 2B). This ketone body has been reported
to stimulate tumor growth and has been associated with cancer
cachexia (Tisdale & Beck, 1990; Shukla et al, 2014), though its role
remains debated (Bonuccelli et al, 2010; Poff et al, 2014; Shukla
et al, 2014). We also identified significant deregulation of less
investigated metabolites. In the blood, tryptophan (VCS = 22/26,
P-value = 3.2 × 104) and histidine (VCS = 14/18, P-value =
1.3 × 102) were among the top three most decreased metabolites
(Fig 2B and C), while they were increased in tumor tissue
(VCS = 8/10, P-value = 4.6 × 102 for both tryptophan and histi-
dine) (Fig 3). Interestingly, histidine has been implicated in tumor-
associated inflammation (Yang et al, 2011), while the tryptophan
metabolite kynurenine (frequently increased in tumor tissue;
VCS = 7/9, P-value = 5.9 × 102; Fig 3) suppresses anti-tumor
immune responses (Opitz et al, 2011). In addition, both tryptophan
and histidine are potential one-carbon donors to tetrahydrofolate,
which contributes to nucleotide metabolism and redox homeostasis,
perhaps reflecting the augmented proliferative potential of cancer
cells. These results indicate that vote counting can identify metabo-
lites that are often up- or downregulated in cancer patients.
Sensitivity analysis
We performed a sensitivity analysis to assess whether the cross-
cancer results were driven/largely influenced by individual cancer
types. To this end, the vote-counting procedure was separately
repeated by excluding in turn each cancer type for studies in urine,
blood, and tissue. The top deregulated metabolites were consistently
deregulated, regardless of which cancer type was taken out of the
analysis, confirming that no individual cancer type dominated the
analysis (not shown).
Type 2 diabetes
To determine whether metabolic alterations could also be detected
with the vote-counting method in another disease, we constructed a
second dataset of blood metabolites in T2DM patients (18 studies,
~1,200 metabolite measurements in estimated 4,000 patients;
Table EV1) and repeated our meta-analysis. Due to the limited
number of CMP studies, the study was relatively underpowered.
Nevertheless, using our approach, we identified a number of vali-
dated T2DM biomarkers, including, as expected, glucose (VCS = 7/7,
P-value = 7.0 × 102). However, we also observed elevations of
the (branched-chain) amino acids leucine (VCS = 9/11, P-value =
7.0 × 102), valine (VCS = 7/11, P-value = 1.1 × 101), isoleucine
(VCS = 5/7, P-value = 1.4 × 101), and phenylalanine (VCS = 7/9,
P-value = 8.8 × 102) (Fig EV3, Table EV6). Interestingly, these
data are consistent with a recent report based on previously
published prospective studies that elevated levels of these amino
acids are associated with an increased risk to develop T2DM
(Guasch-Ferre et al, 2016), thus validating our approach. Further-
more, the same study also found that glycine blood levels were
inversely associated with T2DM risk. Of note, we identified glycine
as the most decreased metabolite in our analysis (VCS = 5/7,
P-value = 1.4 × 101) (Fig EV3, Table EV6). These concordances
further validate the potential of the vote-counting method to iden-
tify changes in metabolites that can be clinically relevant. Another
noteworthy observation is that blood levels of 1,5-anhydrosorbitol
were consistently reduced in all three studies that reported this
metabolite (Table EV6). This metabolite is a clinical biomarker of
diabetes and has been developed in a FDA-approved blood glucose
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Figure 3. Vote-counting analysis in cancer tissue.
Vote counting of cancer tissue metabolites (reported in at least six cohorts) showed consistently deregulated metabolites. Blue bars: decreased metabolites; red bars:
increased metabolites. An asterisk (*) in front of the name of the metabolite indicates at least a statistical trend (P < 0.1) obtained using the sign test; red arrows denote key
metabolites mentioned in the main text (see Table EV5 for full annotation).
Table 1. Metabolomics data reporting.
Cancer All
Blood Urine Tissue cohorts
Median number of
reported metabolites
19 19.5 29 22
Effect size reported (%) 98.5 92 100 97.9
Variance measure
reported (%)
30.8 20 10.3 22.8
Full dataset available (%) 23.1 8 17.9 18.7
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semiquantitative meta-analysis is capable of identifying distinct
metabolite signatures for cancer versus T2DM.
Discussion
Despite incomplete reporting of CMP data, the semiquantitative
meta-analysis approach used in this study was capable of identifying
distinct metabolite signatures in cancer and T2DM. Not only did this
method provide confirmatory evidence for the up- or downregula-
tion of particular metabolites, previously involved in cancer cell
metabolism (Vander Heiden et al, 2009; Lunt & Vander Heiden,
2011), but the approach used also identified metabolites that were
less well/only minimally appreciated in cancer cell metabolism.
While our analysis reveals that meta-analyses of CMP studies
provide novel opportunities, our study was also confronted by a
number of challenges that need to be addressed in order to maxi-
mize the discovery potential of this approach.
Challenges
Despite the promising results of our analysis, several hurdles limit
the amenability of current CMP studies for quantitative meta-
analysis: (i) The lack of availability of full datasets reduces the
statistical power of data mining approaches and precludes re-
analyzing the original data to replicate the results. Moreover, with-
out the availability of full datasets, it is impossible to determine
whether a metabolite was measured but not deemed relevant, or not
measured, leading to a particularly pernicious bias in outcome
reporting that cannot be adequately resolved with current statistical
methods. (ii) Scarce reporting of metadata and lack of raw data for
each analyzed sample limits the possibilities for stratified analysis,
while such analysis of inter-patient heterogeneity is key to modern
personalized medicine. (iii) Many studies use cross-sectional or
case–control research designs to prove that the metabolic profile in
cancer is distinct from controls. Such studies can validate the
discriminatory power of the metabolic profiling technology, but the
results are not necessarily clinically relevant or applicable to
improve personalized medicine. (iv) The use of inconsistent report-
ing formats renders data extraction highly labor-intensive and error-
prone. (v) Ambiguous metabolite annotation and identification limit
confidence in the interpretation of data mining outcomes. (vi) The
lack of quantitative data (absolute levels of metabolites) precludes
the development of reference values to which individual patients
can be compared. (vii) The use of a wide variety of profiling tech-
nologies and analytical methods complicates direct comparison
between studies. And, (viii) the lack of validation in independent
replication cohorts, in preclinical models or by orthogonal experi-
ments, is a shortcoming of many profiling studies.
Opportunities
Nonetheless, despite these limitations, a semiquantitative meta-
analysis of a limited number of studies appeared to be sufficient to
identify a number of known and new metabolites, some under-
scored by a significant P-value, others more by a trend (likely due to
insufficient power). Clearly, standardizing the design, execution,
and reporting of CMP studies will only increase the discovery
potential of quantitative meta-analyses. Today, only a minority of
CMP data is readily available, and retrospective collection and cura-
tion from past publications is an enormous effort. To maximize the
value of CMP studies, metabolomics data could be submitted to a
public metabolomics repository (Haug et al, 2013). Eventually, to
improve the feasibility and power of future data mining approaches,
the research community and journals can adopt reporting standards
that require data annotation in an accessible electronic format
(Larsson & Sandberg, 2006; Rocca-Serra et al, 2016).
Limitations
Our study was designed to test whether a meta-analysis could be
performed with currently available CMP studies in cancer. Given
the aforementioned challenges, the scope of our study was not to
discover new metabolic targets per se, or to create a database for
broad usage. Because comprehensive metabolomics repositories do
not exist, we performed a meta-analysis on reported metabolites, an
approach that is susceptible to publication bias. In conclusion, the
largest limitation is the insufficient number of studies and lack of
full dataset availability, which reduced statistical power, prevented




We performed a meta-analysis of metabolite profiling in cancer with
the following objectives: (i) to provide a cross-section of metabolic
profiling methods and implementations; and (ii) to assess the poten-
tial of metabolomics data mining. The aim of this study was not to
identify, nor to functionally verify new metabolic mechanisms,
discovered through this meta-analysis.
Dataset compilation
General strategy
Since no datasets of metabolic profiling in cancer exist, we first
set out to construct such a dataset. We used a pre-defined search
filter to search MEDLINE for studies reporting on metabolic profil-
ing of blood (plasma and/or serum), tissue, and urine in cancer.
Next, we included studies based on predetermined in- and exclu-
sion criteria (Table EV7) and extracted metabolite data as well as
methodological metadata using a standardized data extraction
sheet. In addition, we noted for each metabolite whether it was
reported as increased or decreased. The same strategy was used
to construct a second dataset of metabolic profiling in type 2
diabetes mellitus (T2DM) in order to assess disease specificity of
identified metabolic alterations.
Search method for identification of studies
Our first search filter combined the search term “metabolic” and
its synonyms with the Boolean operator “OR”. Our second search
filter combined the term “profiling” and its synonyms with the
Boolean operator OR. The third search filter combined the terms
“diabetes” and “cancer” with the operator OR. We then combined
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these searches with the Boolean operator AND. We added addi-
tional filters to specifically exclude studies on metabolic syndrome,
review articles, and editorials. We limited the search to studies
published from June 1, 2010, to June 1, 2015, in the English litera-
ture, to ensure that the data examined reflected current state-of-
the-art profiling platforms. This filter retrieved 4,260 references of
articles. To identify potentially relevant studies, two reviewers
(A.P. and J.G.) independently screened all studies on title and
abstract. To further increase coverage and retrieval of relevant
studies, we complemented our automated search with manual
searches (J.K., L.C.C., and J.G.) in relevant journals and identified
30 additional papers.
Inclusion and exclusion of studies
Next, three teams of two reviewers assessed the eligibility of the
identified papers (A.P./J.G., L.C.C./J.G., J.K./J.G.) by applying
the in- and exclusion criteria. Briefly, we considered global meta-
bolic profiling studies performed in humans, in whom metabolic
profiling was done on serum, plasma, urine, or tumor tissue.
Studies profiling other bodily fluids (such as cerebrospinal fluid
and sweat) and feces only or solely in other organisms were
excluded. We considered both clinical biomarker studies and
studies where metabolic profiling was used as a discovery
strategy to identify novel biological mechanisms. We only
included studies profiling cancer or T2DM that had a well-
defined control group. We further limited inclusion to studies
that used either nuclear magnetic resonance spectroscopy (NMR)
or mass spectrometry (MS) in a global profiling approach. An
overview of included studies is provided in Tables EV8, EV9,
EV10 and EV11.
Quality assessment, data extraction and integrity
For all selected papers, the reviewers used a pre-defined evalua-
tion/data extraction protocol to assess (methodological) study
parameters such as the type of disease, number of patients
included, the analytical platform, outcome, the level of
metabolite identification (see below), and major findings among
others. Because the vast majority of studies annotated reported
metabolites using ambiguous common names and did not use
unique identifiers, which limits bioinformatics possibilities, we
used specific algorithms of the OpenRefine software to standard-
ize spelling and the ConvertTool of the MetaboAnalyst 3.0 soft-
ware to assign unique identifiers if available. Retrospective
manual curation of metabolomics data from published studies is
time-consuming and relatively error-prone, but currently the only
available method to construct a comprehensive metabolomics
dataset. We performed data quality checks at each step of the
dataset construction and randomly re-reviewed 25% of the
included references post-dataset construction.
Metabolite identification levels as defined by the Metabolomics
Standards Initiative
Level “one” (identified metabolites) identification necessitates
that two or more orthogonal properties of an authentic chemi-
cal standard, analyzed in the researcher’s laboratory, are
compared to experimental data acquired in the same laboratory
with the same analytical methods. By contrast, annotation of
level “two” (putatively annotated compounds) and level “three”
(putatively characterized compound classes) does not require
matching to data for authentic chemical standards acquired




Because there are no standardized approaches available for meta-
bolomics meta-analysis and full quantitative data (fold changes,
abundances, etc.) are lacking, we devised a statistical approach to
quantify metabolite deregulation. For each study, a score of “+1”
or “1” was assigned to each reported metabolite, depending on
whether the metabolite was found increased or decreased, respec-
tively, regardless of the fold change. Metabolites that were
reported more than once per study, for example, as measured by
different methods were only annotated once. For these metabo-
lites, we determined directionality (whether it was increased or
decreased) by applying vote counting within the study. This
resulted in an assigned score of “0” if the study reported it
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Problem
It has become increasingly clear that cellular metabolic alterations
are involved in the pathogenesis of multiple diseases, including
cancer. Clinical metabolic profiling (CMP) offers the opportunity to
characterize the metabolome and is being increasingly used to iden-
tify disease-associated metabolic signatures. Metabolic profiling of
body fluids and excretions such as blood, urine, and feces was antici-
pated to identify novel biomarkers, while profiling of diseased tissue
was expected to provide insight into molecular pathogenesis.
However, despite technological advances and increasing use of CMP,
progress and clinical translation of these data have been more modest
than expected. Surprisingly, a meta-analysis of CMP has not been
performed, even though (i) such studies could provide insight into
current methods and application of metabolic profiling; and (ii) similar
meta-analyses have contributed to the impact in the genomics, tran-
scriptomics and proteomics fields. Here, we performed a meta-analysis
of CMP in cancer.
Results
We manually compiled a dataset of cancer studies published during
five recent years. Insufficient raw data and metadata availability and
reporting prevented quantitative meta-analysis. We therefore
performed a semiquantitative meta-analysis by vote counting (com-
paring the number of studies that report a metabolite to be increased
or decreased in order to identify metabolites that are consistently
deregulated across studies) to demonstrate the potential of CMP data
mining, as highlighted by the identification of several known but also
previously less appreciated metabolic alterations in cancer.
Impact
Our results suggest that the clinical impact of metabolic profiling
could be improved by adhering to standards for designing clinical
studies, more extensive validation of the results and, most impor-
tantly, by improved metabolomics data reporting (and metabolite
identification) and deposition of full datasets in public repositories for
reuse in meta-studies. Scientific journals may facilitate this process by
demanding full dataset availability as is already required for geno-
mics, transcriptomics, and proteomics data.
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equally often as increased and decreased, because directionality
could not be determined (21, 42, and 1 metabolite in blood,
urine, and tissue samples, respectively). We then performed a
semiquantitative meta-analysis by vote counting, that is, summing
the scores for each metabolite, to quantify deregulation (i.e. the
consistency with which a metabolite is reported to be increased
or decreased across studies). The vote-counting statistic (VCS,
reported as VCS/number of reporting studies; Benjamini–
Hochberg adjusted P-value) assumes a high positive value if the
metabolite is consistently increased, and conversely a negative
value for consistently decreased metabolites. In this context, a
zero value implies that the studies provide conflicting evidence
on whether the metabolite is increased or decreased.
We also used the sign test to assign a P-value to assess whether
the vote-counting results were merely due to chance. The null
hypothesis was that the directionality of deregulation of a given
metabolite is not consistent across studies. Under this null hypoth-
esis, we assumed that studies would report the metabolite as
either increased or decreased with approximately equal probabil-
ity. With this assumption, we could model the global score for a
given metabolite as the result of a binomial process, where (i) the
number of trials equals the number of studies reporting the
metabolite, (ii) success is defined as a study with the same sign of
the global score, and (iii) the probability of success is set to 0.5.
The one-tailed P-value assessing the probability of obtaining an
equal or greater (in absolute terms) global score under the null
hypothesis was obtained from the binomial distribution and
adjusted for multiple testing with the Benjamini–Hochberg proce-
dure (Benjamini & Hochberg, 1995). The significance of metabo-
lites reported in 5 or fewer studies was not assessed for lack of
statistical evidence.
An alternative, permutation-based test was also employed. For
each metabolite, the null distribution was built by computing
several times the global score on a simulated set of reporting stud-
ies. Each simulated set was built by randomly assigning with proba-
bility 0.5 an up/down directionality to each study reporting the
metabolite. A one-tailed P-value was computed by comparing the
original global score against its respective null distribution. The
results of this permutation test were almost identical to the P-values
provided by the binomial test (correlation > 0.9) and are thus not
reported.
Expanded View for this article is available online.
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